Cholangiocarcinoma Australia Webinar Review 2025
Full review of the Cholangiocarcinoma Foundation Australia’s 2025 webinar. Key insights on genomic profiling, treatment gaps, and steps to national care standards.
FGFR2 Fusion The Fourth Domino
FGFR2 fusion isn't the start—it’s the tipping point. Understand how it transforms duct damage into cancer, and the steps you can take now to respond.
FGFR2 Mutation Drives Cholangiocarcinoma
FGFR2 mutation drives cholangiocarcinoma by trigger nonstop cell growth by fusing two genes into a rogue hybrid. This article explains how the mutation forms, what goes wrong, and how therapies like Pemigatinib and Futibatinib work to shut down the chaos and restore balance.
Pemazyre – The FGFR2 Circuit Breaker
Pemazyre – The Circuit Breaker: A targeted FGFR inhibitor that disrupts tumor growth by blocking the upstream signal driving cholangiocarcinoma. For patients with FGFR2 fusions, it’s not just a treatment — it’s a turning point.
Dr Chris Rogan at APSCVIR – Through The Cholangio Lens
Cholangiocarcinoma is often overlooked. Dr Chris Rogan highlights liver-directed therapy and calls for World IR Day to reshape access and awareness.
Reprogramming Bile Duct Cancer Tumours
Mini tumors and RNA-based tools are helping reprogram bile duct cancer — guiding smarter treatments and reshaping how patients survive.
Cholangiocarcinoma Australia Webinar Review 2025
Full review of the Cholangiocarcinoma Foundation Australia’s 2025 webinar. Key insights on genomic profiling, treatment gaps, and steps to national care standards.
FGFR2 Fusion The Fourth Domino
FGFR2 fusion isn't the start—it’s the tipping point. Understand how it transforms duct damage into cancer, and the steps you can take now to respond.
FGFR2 Mutation Drives Cholangiocarcinoma
FGFR2 mutation drives cholangiocarcinoma by trigger nonstop cell growth by fusing two genes into a rogue hybrid. This article explains how the mutation forms, what goes wrong, and how therapies like Pemigatinib and Futibatinib work to shut down the chaos and restore balance.
Pemazyre – The FGFR2 Circuit Breaker
Pemazyre – The Circuit Breaker: A targeted FGFR inhibitor that disrupts tumor growth by blocking the upstream signal driving cholangiocarcinoma. For patients with FGFR2 fusions, it’s not just a treatment — it’s a turning point.
Dr Chris Rogan at APSCVIR – Through The Cholangio Lens
Cholangiocarcinoma is often overlooked. Dr Chris Rogan highlights liver-directed therapy and calls for World IR Day to reshape access and awareness.
Reprogramming Bile Duct Cancer Tumours
Mini tumors and RNA-based tools are helping reprogram bile duct cancer — guiding smarter treatments and reshaping how patients survive.
